Laboratory Management
Please note:
Adobe PDF Reader is required to view clinical guideline documents.
There may be instances in which your health plan policies take precedence over the EviCore by Evernorth clinical guidelines. If you have any questions, please reach out to your health plan.
Follow the below steps to access the clinical guidelines.
- Enter your Health Plan name into the search field and click on the magnifying glass.
- To access the guideline specific to your request, locate the guideline that the decision was based on from within your letter.
- Identify the guideline title and then search for that guideline title by scrolling down on the page or entering the guideline title into the guideline title search field.
- Open the guideline document.
Example:
The statement in your letter reads:
We based this decision on the guideline as listed below:
-MTHFR Variant Analysis for Hyperhomocysteinemia (MOL.TX.205).
Enter your Health Plan name into the search field and click on the magnifying glass.
Enter the guideline title into the search field for the guideline name.
Once the search results appear, click on the guideline to open it.
If you require a copy of the guidelines that were used to make a determination on a specific request of treatment or services, please email the case number and request to: reqcriteria@EviCore.com.
To request any additional assistance in accessing the guidelines, provide feedback or clinical evidence related to the evidence-based guidelines, please click here.
EviCore coverage policies include background and supporting information and citations for sources used to develop the policy. Some clinical policies may have a supplemental literature summary available which will provide additional commentary regarding clinical benefits and harms to the patient population being served. Additional literature summaries may be accessed by selecting ‘Supplemental Information’ and then entering “EviCore by Evernorth” in the search by health plan function.
Code Lists
Guidelines
-
Amerihealth Caritas Lab Guideline ManualEffective 07/01/2023 - 12/31/2023
-
AmeriHealth Caritas Lab Management GuidelinesEffective 01/01/2024 - 01/11/2024
-
AmeriHealth Lab Caritas Management Guidelines - Effective Date: To Be DeterminedEffective 06/01/2023 - 06/30/2023
-
MOL.AD.107.A: Unique Test Identifiers for Non-Specific Procedure CodesEffective 01/01/2024 - 01/11/2024
-
MOL.AD.107.A:Unique Test Identifiers for Non-Specific Procedure CodesEffective 07/01/2023 - 12/31/2023
-
MOL.AD.304.A: Medical Necessity Review Information RequirementsEffective 01/01/2024 - 01/11/2024
-
MOL.AD.304.A:Medical Necessity Review Information RequirementsEffective 07/01/2023 - 12/31/2023
-
MOL.AD.314.A: Date of Service and Authorization Period Effective DateEffective 01/01/2024 - 01/11/2024
-
MOL.AD.314.A:Date of Service and Authorization Period Effective DateEffective 07/01/2023 - 12/31/2023
-
MOL.AD.330.A:Hierarchy for Applying Coverage Decisions for Laboratory Testing for Medicare-Medicaid Dual Eligible MembersEffective 07/01/2023 - 12/31/2023
-
MOL.AD.364.A: Special Circumstances Influencing Coverage DeterminationsEffective 01/01/2024 - 01/11/2024
-
MOL.AD.364.A:Special Circumstances Influencing Coverage DeterminationsEffective 07/01/2023 - 12/31/2023
-
MOL.AD.391.A: Laboratory Procedure Code RequirementsEffective 01/01/2024 - 01/11/2024
-
MOL.AD.391.A:Laboratory Procedure Code RequirementsEffective 07/01/2023 - 12/31/2023
-
MOL.AD.378.AC: Medicaid: Hierarchy for Applying Coverage Decisions for Laboratory Testing for AmeriHealth Caritas Managed Medicaid Members in the State of DelawareEffective 01/01/2024 - 01/11/2024
-
MOL.AD.378.AC:Medicaid: Hierarchy for Applying Coverage Decisions for Laboratory Testing for AmeriHealth Caritas Managed Medicaid Members in the State of DelawareEffective 07/01/2023 - 12/31/2023
-
MOL.AD.379.AC: Medicaid: Hierarchy for Applying Coverage Decisions for Laboratory Testing for AmeriHealth Caritas Managed Medicaid Members in the State of DelawareEffective 07/01/2023 - 12/31/2023
-
MOL.AD.379.AC: Medicaid: Hierarchy for Applying Coverage Decisions for Laboratory Testing for AmeriHealth Caritas Managed Medicaid Members in the State of FloridaEffective 01/01/2024 - 01/11/2024
-
MOL.AD.380.AC: Medicaid: Hierarchy for Applying Coverage Decisions for Laboratory Testing for AmeriHealth Caritas Managed Medicaid Members in the State of MichiganEffective 01/01/2024 - 01/11/2024
-
MOL.AD.380.AC:Medicaid: Hierarchy for Applying Coverage Decisions for Laboratory Testing for AmeriHealth Caritas Managed Medicaid Members in the State of MichiganEffective 07/01/2023 - 12/31/2023
-
MOL.AD.381.AC: Medicaid: Hierarchy for Applying Coverage Decisions for Laboratory Testing for AmeriHealth Caritas Managed Medicaid Members in the State of North CarolinaEffective 01/01/2024 - 01/11/2024
-
MOL.AD.381.AC:Medicaid: Hierarchy for Applying Coverage Decisions for Laboratory Testing for AmeriHealth Caritas Managed Medicaid Members in the State of North CarolinaEffective 07/01/2023 - 12/31/2023
-
MOL.AD.382.AC: Medicaid: Hierarchy for Applying Coverage Decisions for Laboratory Testing for AmeriHealth Caritas Managed Medicaid Members in the State of South CarolinaEffective 01/01/2024 - 01/11/2024
-
MOL.AD.382.AC:Medicaid: Hierarchy for Applying Coverage Decisions for Laboratory Testing for AmeriHealth Caritas Managed Medicaid Members in the State of South CarolinaEffective 07/01/2023 - 12/31/2023
-
MOL.AD.383.AC: Medicaid: Hierarchy for Applying Coverage Decisions for Laboratory Testing for AmeriHealth Caritas Managed Medicaid Members in the State of OhioEffective 01/01/2024 - 01/11/2024
-
MOL.AD.383.AC:Medicaid: Hierarchy for Applying Coverage Decisions for Laboratory Testing for AmeriHealth Caritas Managed Medicaid Members in the State of OhioEffective 07/01/2023 - 12/31/2023
-
MOL.AD.385.AC: Medicaid: Hierarchy for Applying Coverage Decisions for Laboratory Testing for AmeriHealth Caritas Managed Medicaid Members in the State of LouisianaEffective 01/01/2024 - 01/11/2024
-
MOL.AD.385.AC:Medicaid: Hierarchy for Applying Coverage Decisions for Laboratory Testing for AmeriHealth Caritas Managed Medicaid Members in the StateEffective 07/01/2023 - 12/31/2023
-
MOL.AD.386.AC: Medicaid: Hierarchy for Applying Coverage Decisions for Laboratory Testing for AmeriHealth Caritas Managed Medicaid Members in the State of PennsylvaniaEffective 01/01/2024 - 01/11/2024
-
MOL.AD.386.AC:Medicaid: Hierarchy for Applying Coverage Decisions for Laboratory Testing for AmeriHealth Caritas Managed Medicaid Members in the State of PennsylvaniaEffective 07/01/2023 - 12/31/2023
-
MOL.AD.387.AC: Medicaid: Hierarchy for Applying Coverage Decisions for Laboratory Testing for AmeriHealth Caritas Managed Medicaid Members in Washington D.C.Effective 01/01/2024 - 01/11/2024
-
MOL.AD.387.AC:Medicaid: Hierarchy for Applying Coverage Decisions for Laboratory Testing for AmeriHealth Caritas Managed Medicaid Members in Washington D.C.Effective 07/01/2023 - 12/31/2023
-
MOL.AD.388.AC:Medicaid: Hierarchy for Applying Coverage Decisions for Laboratory Testing for AmeriHealth Caritas Managed Medicaid Members in the State of New HampshireEffective 07/01/2023 - 12/31/2023
-
MOL.AD.101.A:Medicare:Hierarchy for Applying Coverage Decisions for Laboratory TestingEffective 07/01/2023 - 12/31/2023
-
MOL.AD.101.B: Medicare: Hierarchy for Applying Coverage Decisions for Laboratory TestingEffective 01/01/2024 - 01/11/2024
-
MOL.AD.330.A: Hierarchy for Applying Coverage Decisions for Laboratory Testing for Medicare-Medicaid Dual Eligible MembersEffective 01/01/2024 - 01/11/2024
-
MOL.CU.109.A: Genetic Testing for Cancer Susceptibility and Hereditary Cancer SyndromesEffective 01/01/2024 - 01/11/2024
-
MOL.CU.109.A:Genetic Testing for Cancer Susceptibility and Hereditary Cancer SyndromesEffective 07/01/2023 - 12/31/2023
-
MOL.CU.110.A: Genetic Testing for Carrier StatusEffective 01/11/2024 - 01/11/2024
-
MOL.CU.110.A:Genetic Testing for Carrier StatusEffective 07/01/2023 - 12/31/2023
-
MOL.CU.111.A: Genetic Testing for Non-Medical PurposesEffective 01/01/2024 - 01/11/2024
-
MOL.CU.111.A:Genetic Testing for Non-Medical PurposesEffective 07/01/2023 - 12/31/2023
-
MOL.CU.112.A: Genetic Testing for Prenatal Screening and Diagnostic TestingEffective 01/01/2024 - 01/11/2024
-
MOL.CU.112.A:Genetic Testing for Prenatal Screening and Diagnostic TestingEffective 07/01/2023 - 12/31/2023
-
MOL.CU.113.A: Genetic Testing for the Screening, Diagnosis, and Monitoring of CancerEffective 01/01/2024 - 01/11/2024
-
MOL.CU.113.A:Genetic Testing for the Screening, Diagnosis, and Monitoring of CancerEffective 07/01/2023 - 12/31/2023
-
MOL.CU.114.A: Genetic Testing to Diagnose Non-Cancer ConditionsEffective 01/01/2024 - 01/11/2024
-
MOL.CU.114.A:Genetic Testing to Diagnose Non-Cancer ConditionsEffective 07/01/2023 - 12/31/2023
-
MOL.CU.115.A: Genetic Testing to Predict Disease RiskEffective 01/01/2024 - 01/11/2024
-
MOL.CU.115.A:Genetic Testing to Predict Disease RiskEffective 07/01/2023 - 12/31/2023
-
MOL.CU.116.A: Genetic Testing by Multigene PanelsEffective 01/01/2024 - 01/11/2024
-
MOL.CU.116.A:Genetic Testing by Multigene PanelsEffective 07/01/2023 - 12/31/2023
-
MOL.CU.117.A: Investigational and Experimental Laboratory TestingEffective 01/01/2024 - 01/11/2024
-
MOL.CU.117.A:Investigational and Experimental Laboratory TestingEffective 07/01/2023 - 12/31/2023
-
MOL.CU.118.A: Pharmacogenomic Testing for Drug Toxicity and ResponseEffective 01/01/2024 - 01/11/2024
-
MOL.CU.118.A:Pharmacogenomic Testing for Drug Toxicity and ResponseEffective 07/01/2023 - 12/31/2023
-
MOL.CU.119.A: Preimplantation Genetic Screening and DiagnosisEffective 01/01/2024 - 01/11/2024
-
MOL.CU.119.A:Preimplantation Genetic Screening and DiagnosisEffective 07/01/2023 - 12/31/2023
-
MOL.CU.246.A: Hereditary (Germline) Testing After Tumor (Somatic) TestingEffective 01/01/2024 - 01/11/2024
-
MOL.CU.246.A:Hereditary (Germline) Testing After Tumor (Somatic) TestingEffective 07/01/2023 - 12/31/2023
-
MOL.CU.256.A: Confirmatory Genetic TestingEffective 01/01/2024 - 01/11/2024
-
MOL.CU.256.A:Confirmatory Genetic TestingEffective 07/01/2023 - 12/31/2023
-
MOL.CU.291.A: Genetic Testing for Known Familial MutationsEffective 01/01/2024 - 01/11/2024
-
MOL.CU.291.A:Genetic Testing for Known Familial MutationsEffective 07/01/2023 - 12/31/2023
-
MOL.CU.292.A: Genetic Testing for Variants of Uncertain Clinical SignificanceEffective 01/01/2024 - 01/11/2024
-
MOL.CU.292.A:Genetic Testing for Variants of Uncertain Clinical SignificanceEffective 07/01/2023 - 12/31/2023
-
MOL.CU.298.A:Genetic Presymptomatic and Predictive Testing for Adult-Onset Conditions in MinorsEffective 07/01/2023 - 12/31/2023
-
MOL.CU.398.A: Infectious Disease Laboratory TestingEffective 01/01/2024 - 01/11/2024
-
MOL.CS.103.A:Flow CytometryEffective 07/01/2023 - 12/31/2023
-
MOL.CS.104.A: Immunohistochemistry (IHC)Effective 01/01/2024 - 01/11/2024
-
MOL.CS.104.A:Immunohistochemistry (IHC)Effective 07/01/2023 - 12/31/2023
-
MOL.CS.105.A: Laboratory Claim ReimbursementEffective 01/01/2024 - 01/11/2024
-
MOL.CS.105.A:Laboratory Claim ReimbursementEffective 07/01/2023 - 12/31/2023
-
MOL.CS.106.A: Sexually Transmitted and Other Reproductive Tract Infection TestingEffective 01/01/2024 - 01/11/2024
-
MOL.CS.106.A:Genitourinary Conditions Molecular TestingEffective 07/01/2023 - 12/31/2023
-
MOL.CS.108.A: UroVysion FISH for Bladder CancerEffective 01/01/2024 - 01/11/2024
-
MOL.CS.108.A:UroVysion FISH for Bladder CancerEffective 07/01/2023 - 12/31/2023
-
MOL.CS.146.A: HLA Typing for Celiac DiseaseEffective 01/01/2024 - 01/11/2024
-
MOL.CS.146.A:HLA Typing for Celiac DiseaseEffective 07/01/2023 - 12/31/2023
-
MOL.CS.185.A: HIV Tropism Testing for Maraviroc ResponseEffective 01/01/2024 - 01/11/2024
-
MOL.CS.185.A:HIV Tropism Testing for Maraviroc ResponseEffective 07/01/2023 - 12/31/2023
-
MOL.CS.218.A: Prenatal Aneuploidy FISH TestingEffective 01/01/2024 - 01/11/2024
-
MOL.CS.218.A:Prenatal Aneuploidy FISH TestingEffective 07/01/2023 - 12/31/2023
-
MOL.CS.277.A: Gastrointestinal Pathogen Panel (GIPP) Molecular TestingEffective 01/01/2024 - 01/11/2024
-
MOL.CS.277.A:Molecular Gastrointestinal Pathogen Panel (GIPP) TestingEffective 07/01/2023 - 12/31/2023
-
MOL.CS.289.A: Chromosome Analysis for Reproductive Disorders, Prenatal Testing, and Developmental DisordersEffective 01/01/2024 - 01/11/2024
-
MOL.CS.289.A:Chromosome Analysis for Reproductive Disorders, Prenatal Testing, and Developmental DisordersEffective 07/01/2023 - 12/31/2023
-
MOL.CS.293.A Respiratory Infection Pathogen Panel (RIPP) Molecular TestingEffective 01/01/2024 - 01/11/2024
-
MOL.CS.293.A:Molecular Respiratory Infection Pathogen Panel (RIPP) TestingEffective 07/01/2023 - 12/31/2023
-
MOL.CS.321.A: Human Immunodeficiency Virus Laboratory TestingEffective 01/01/2024 - 01/11/2024
-
MOL.CS.321.A:Human Immunodeficiency Virus Laboratory TestingEffective 07/01/2023 - 12/31/2023
-
MOL.CS.332.A: Lyme Disease TestingEffective 01/01/2024 - 01/11/2024
-
MOL.CS.332.A:Lyme Disease TestingEffective 07/01/2023 - 12/31/2023
-
MOL.CS.333.A: Medically Necessary Laboratory TestingEffective 01/01/2024 - 01/11/2024
-
MOL.CS.333.A:Medically Necessary Laboratory TestingEffective 07/01/2023 - 12/31/2023
-
MOL.CS.353.A: SARS-CoV-2 (COVID-19) Laboratory TestingEffective 01/01/2024 - 01/11/2024
-
MOL.CS.353.A:SARS-CoV-2 (COVID-19) Laboratory TestingEffective 07/01/2023 - 12/31/2023
-
MOL.CS.362.A: Human Papillomavirus (HPV) Molecular TestingEffective 01/01/2024 - 01/11/2024
-
MOL.CS.362.A:Human Papillomavirus (HPV) Molecular TestingEffective 07/01/2023 - 12/31/2023
-
MOL.CS.363.A: Pathology Testing with Mohs Micrographic SurgeryEffective 01/01/2024 - 01/11/2024
-
MOL.CS.363.A:Pathology Testing with Mohs Micrographic SurgeryEffective 07/01/2023 - 12/31/2023
-
MOL.CS.402.A: Nail Disorder Infectious Disease Testing, Including OnychomycosisEffective 01/01/2024 - 01/11/2024
-
MOL.CS.403.A: Urinary Tract Infection Molecular TestingEffective 01/01/2024 - 01/11/2024
-
MOL.TS.120.A: 4Kscore for Prostate Cancer Risk AssessmentEffective 01/01/2024 - 01/11/2024
-
MOL.TS.120.A:4Kscore for Prostate Cancer Risk AssessmentEffective 07/01/2023 - 12/31/2023
-
MOL.TS.122.A: Afirma Thyroid Cancer Classifier TestsEffective 01/01/2024 - 01/11/2024
-
MOL.TS.122.A:Afirma Thyroid Cancer Classifier TestsEffective 07/01/2023 - 12/31/2023
-
MOL.TS.123.A:AlloMap Gene Expression Profiling for Heart Transplant RejectionEffective 07/01/2023 - 12/31/2023
-
MOL.TS.123.A_AlloMap Gene Expression Profiling For Heart Transplant RejectionEffective 01/01/2024 - 01/11/2024
-
MOL.TS.124.A: Alpha-1 Antitrypsin Deficiency TestingEffective 01/01/2024 - 01/11/2024
-
MOL.TS.124.A:Alpha-1 Antitrypsin Deficiency TestingEffective 07/01/2023 - 12/31/2023
-
MOL.TS.125.A: Amyotrophic Lateral Sclerosis (ALS) Genetic TestingEffective 01/01/2024 - 01/11/2024
-
MOL.TS.125.A:Amyotrophic Lateral Sclerosis (ALS) Genetic TestingEffective 07/01/2023 - 12/31/2023
-
MOL.TS.126.A: Angelman Syndrome Genetic TestingEffective 01/01/2024 - 01/11/2024
-
MOL.TS.126.A:Angelman Syndrome Genetic TestingEffective 07/01/2023 - 12/31/2023
-
MOL.TS.128.A: APOE Variant Analysis for Alzheimer Disease TestingEffective 01/01/2024 - 01/11/2024
-
MOL.TS.128.A:APOE Variant Analysis for Alzheimer Disease TestingEffective 07/01/2023 - 12/31/2023
-
MOL.TS.129.A: Ashkenazi Jewish Carrier ScreeningEffective 01/01/2024 - 01/11/2024
-
MOL.TS.129.A:Ashkenazi Jewish Carrier ScreeningEffective 07/01/2023 - 12/31/2023
-
MOL.TS.130.A: Ataxia-Telangiectasia Genetic TestingEffective 01/01/2024 - 01/11/2024
-
MOL.TS.130.A:Ataxia-Telangiectasia Genetic TestingEffective 07/01/2023 - 12/31/2023
-
MOL.TS.132.A: Bloom Syndrome Genetic TestingEffective 01/01/2024 - 01/11/2024
-
MOL.TS.132.A:Bloom Syndrome Genetic TestingEffective 07/01/2023 - 12/31/2023
-
MOL.TS.144.A: CADASIL Genetic TestingEffective 01/01/2024 - 01/11/2024
-
MOL.TS.144.A:CADASIL Genetic TestingEffective 07/01/2023 - 12/31/2023
-
MOL.TS.145.A: Canavan Disease Genetic TestingEffective 01/01/2024 - 01/11/2024
-
MOL.TS.145.A:Canavan Disease Genetic TestingEffective 07/01/2023 - 12/31/2023
-
MOL.TS.148.A: Charcot-Marie-Tooth Neuropathy TestingEffective 01/01/2024 - 01/11/2024
-
MOL.TS.148.A:Charcot-Marie-Tooth Neuropathy TestingEffective 07/01/2023 - 12/31/2023
-
MOL.TS.149.A: Chromosomal Microarray for Prenatal DiagnosisEffective 01/01/2024 - 01/11/2024
-
MOL.TS.149.A:Chromosomal Microarray for Prenatal DiagnosisEffective 07/01/2023 - 12/31/2023
-
MOL.TS.150.A: Chromosomal Microarray Testing For Developmental DisordersEffective 01/01/2024 - 01/11/2024
-
MOL.TS.150.A:Chromosomal Microarray Testing For Developmental DisordersEffective 07/01/2023 - 12/31/2023
-
MOL.TS.151.A: Chromosome Analysis for Blood and Bone Marrow CancersEffective 01/01/2024 - 01/11/2024
-
MOL.TS.151.A:Chromosome Analysis for Blood and Bone Marrow CancersEffective 07/01/2023 - 12/31/2023
-
MOL.TS.152.A: Cologuard Screening for Colorectal CancerEffective 01/01/2024 - 01/11/2024
-
MOL.TS.152.ACologuard Screening for Colorectal CancerEffective 07/01/2023 - 12/31/2023
-
MOL.TS.153.A: ConfirmMDx for Prostate Cancer Risk AssessmentEffective 01/01/2024 - 01/11/2024
-
MOL.TS.153.A:ConfirmMDx for Prostate Cancer Risk AssessmentEffective 07/01/2023 - 12/31/2023
-
MOL.TS.158.A: Cystic Fibrosis Genetic TestingEffective 01/01/2024 - 01/11/2024
-
MOL.TS.158.A:Cystic Fibrosis Genetic TestingEffective 07/01/2023 - 12/31/2023
-
MOL.TS.159.A: Dentatorubral-Pallidoluysian Atrophy Genetic TestingEffective 01/01/2024 - 01/11/2024
-
MOL.TS.159.A:Dentatorubral-Pallidoluysian Atrophy Genetic TestingEffective 07/01/2023 - 12/31/2023
-
MOL.TS.161.A: Duchenne and Becker Muscular Dystrophy TestingEffective 01/01/2024 - 01/11/2024
-
MOL.TS.161.A:Duchenne and Becker Muscular Dystrophy Genetic TestingEffective 07/01/2023 - 12/31/2023
-
MOL.TS.162.A: Early Onset Familial Alzheimer Disease Genetic TestingEffective 01/01/2024 - 01/11/2024
-
MOL.TS.162.A:Early Onset Familial Alzheimer Disease Genetic TestingEffective 07/01/2023 - 12/31/2023
-
MOL.TS.164.A:SEPT9 Methylation Analysis for Colorectal CancerEffective 07/01/2023 - 12/31/2023
-
MOL.TS.165.A: Expanded Carrier Screening PanelsEffective 01/01/2024 - 01/11/2024
-
MOL.TS.165.A:Expanded Carrier Screening PanelsEffective 07/01/2023 - 12/31/2023
-
MOL.TS.168.A:Familial Adenomatous Polyposis Genetic TestingEffective 07/01/2023 - 12/31/2023
-
MOL.TS.169.A: Familial Hypercholesterolemia Genetic TestingEffective 01/01/2024 - 01/11/2024
-
MOL.TS.169.A:Familial Hypercholesterolemia Genetic TestingEffective 07/01/2023 - 12/31/2023
-
MOL.TS.170.A: Familial Malignant Melanoma Genetic TestingEffective 01/01/2024 - 01/11/2024
-
MOL.TS.170.A:Familial Malignant Melanoma Genetic TestingEffective 07/01/2023 - 12/31/2023
-
MOL.TS.172.A: FMR1-Related Disorders (Fragile X) Genetic TestingEffective 01/01/2024 - 01/11/2024
-
MOL.TS.172.A:FMR1-Related Disorders (Fragile X) Genetic TestingEffective 07/01/2023 - 12/31/2023
-
MOL.TS.173.A: Gaucher Disease Genetic TestingEffective 01/01/2024 - 01/11/2024
-
MOL.TS.173.A:Gaucher Disease Genetic TestingEffective 07/01/2023 - 12/31/2023
-
MOL.TS.182.A: Hereditary Cancer Syndrome Multigene PanelsEffective 01/01/2024 - 01/11/2024
-
MOL.TS.182.A:Hereditary Cancer Syndrome Multigene PanelsEffective 07/01/2023 - 12/31/2023
-
MOL.TS.183.A: HFE Hemochromatosis Genetic TestingEffective 01/01/2024 - 01/11/2024
-
MOL.TS.183.A:HFE Hemochromatosis TestingEffective 07/01/2023 - 12/31/2023
-
MOL.TS.188.A:Huntington DiseaseEffective 07/01/2023 - 12/31/2023
-
MOL.TS.189.A:Hypertrophic Cardiomyopathy Genetic TestingEffective 07/01/2023 - 12/31/2023
-
MOL.TS.193.A: Li-Fraumeni Syndrome Genetic TestingEffective 01/01/2024 - 01/11/2024
-
MOL.TS.193.A:Li-Fraumeni Syndrome Genetic TestingEffective 07/01/2023 - 12/31/2023
-
MOL.TS.194.A: Liquid Biopsy TumorsEffective 01/01/2024 - 01/11/2024
-
MOL.TS.194.A:Liquid Biopsy TestingEffective 07/01/2023 - 12/31/2023
-
MOL.TS.196.A: Long QT Syndrome Genetic TestingEffective 01/01/2024 - 01/11/2024
-
MOL.TS.196.A:Long QT Syndrome Genetic TestingEffective 07/01/2023 - 12/31/2023
-
MOL.TS.197.A: Lynch Syndrome Genetic TestingEffective 01/01/2024 - 01/11/2024
-
MOL.TS.197.A:Lynch Syndrome Genetic TestingEffective 07/01/2023 - 12/31/2023
-
MOL.TS.199.A: Lynch Syndrome Tumor Screening - Second-TierEffective 01/01/2024 - 01/11/2024
-
MOL.TS.199.A:Lynch Syndrome Tumor Screening - Second-TierEffective 07/01/2023 - 12/31/2023
-
MOL.TS.200.A: Mammaprint 70-Gene Breast Cancer Recurrence AssayEffective 01/01/2024 - 01/11/2024
-
MOL.TS.200.A:MammaPrint 70-Gene Breast Cancer Recurrence AssayEffective 07/01/2023 - 12/31/2023
-
MOL.TS.202.A: Marfan Syndrome Genetic TestingEffective 01/01/2024 - 01/11/2024
-
MOL.TS.202.A:Marfan Syndrome Genetic TestingEffective 07/01/2023 - 12/31/2023
-
MOL.TS.206.A: MUTYH-Associated Polyposis Genetic TestingEffective 01/01/2024 - 01/11/2024
-
MOL.TS.206.A:MUTYH-Associated Polyposis Genetic TestingEffective 07/01/2023 - 12/31/2023
-
MOL.TS.207.A: Niemann-Pick Disease Types A and B Genetic TestingEffective 01/01/2024 - 01/11/2024
-
MOL.TS.207.A:Niemann-Pick Disease Types A and B TestingEffective 07/01/2023 - 12/31/2023
-
MOL.TS.208.A: Niemann-Pick Disease Type C Genetic TestingEffective 01/01/2024 - 01/11/2024
-
MOL.TS.208.A:Niemann-Pick Disease Type C TestingEffective 07/01/2023 - 12/31/2023
-
MOL.TS.209.A: Non-Invasive Prenatal ScreeningEffective 01/01/2024 - 01/11/2024
-
MOL.TS.209.A:Non-Invasive Prenatal ScreeningEffective 07/01/2023 - 12/31/2023
-
MOL.TS.211.A: Oncotype DX for Breast Cancer PrognosisEffective 01/01/2024 - 01/11/2024
-
MOL.TS.211.A:Oncotype DX for Breast Cancer PrognosisEffective 07/01/2023 - 12/31/2023
-
MOL.TS.213.A: Oncotype DX for Colorectal Cancer Recurrence RiskEffective 01/01/2024 - 01/11/2024
-
MOL.TS.213.A:Oncotype DX for Colorectal Cancer Recurrence RiskEffective 07/01/2023 - 12/31/2023
-
MOL.TS.215.A: PCA3 Testing for Prostate CancerEffective 01/01/2024 - 01/11/2024
-
MOL.TS.215.A:PCA3 Testing for Prostate CancerEffective 07/01/2023 - 12/31/2023
-
MOL.TS.216.A: Peutz-Jeghers Syndrome Genetic TestingEffective 01/01/2024 - 01/11/2024
-
MOL.TS.216.A:Peutz-Jeghers Syndrome Genetic TestingEffective 07/01/2023 - 12/31/2023
-
MOL.TS.217.A: Prader-Willi Syndrome Genetic TestingEffective 01/01/2024 - 01/11/2024
-
MOL.TS.217.A:Prader-Willi Syndrome Genetic TestingEffective 07/01/2023 - 12/31/2023
-
MOL.TS.220.A: Prenatal Maternal Serum ScreeningEffective 01/01/2024 - 01/11/2024
-
MOL.TS.220.A:Prenatal Maternal Serum ScreeningEffective 07/01/2023 - 12/31/2023
-
MOL.TS.222.A:Prosigna Breast Cancer Prognostic Gene Signature AssayEffective 07/01/2023 - 12/31/2023
-
MOL.TS.223.A: PTEN Hamartoma Tumor Syndromes Genetic TestingEffective 01/01/2024 - 01/11/2024
-
MOL.TS.223.A:PTEN Hamartoma Tumor Syndromes Genetic TestingEffective 07/01/2023 - 12/31/2023
-
MOL.TS.224.A: Rett Syndrome Genetic TestingEffective 01/01/2024 - 01/11/2024
-
MOL.TS.224.A:Rett Syndrome Genetic TestingEffective 07/01/2023 - 12/31/2023
-
MOL.TS.225.A: Spinal Muscular Atrophy Genetic TestingEffective 01/01/2024 - 01/11/2024
-
MOL.TS.225.A:Spinal Muscular Atrophy TestingEffective 07/01/2023 - 12/31/2023
-
MOL.TS.226.A: Tay-Sachs Disease Genetic TestingEffective 01/01/2024 - 01/11/2024
-
MOL.TS.226.A:Tay-Sachs Disease Genetic TestingEffective 07/01/2023 - 12/31/2023
-
MOL.TS.227.A: Thoracic Aortic Aneurysms and Dissections (TAAD) Panel Genetic TestingEffective 01/01/2024 - 01/11/2024
-
MOL.TS.227.A:Thoracic Aortic Aneurysms and Dissections (TAAD) Panel TestingEffective 07/01/2023 - 12/31/2023
-
MOL.TS.228.A: Tissue of Origin Testing for Cancer of Unknown PrimaryEffective 01/01/2024 - 01/11/2024
-
MOL.TS.228.A:Tissue of Origin Testing for Cancer of Unknown PrimaryEffective 07/01/2023 - 12/31/2023
-
MOL.TS.230.A: Somatic Mutation Testing-Solid TumorsEffective 01/01/2024 - 01/11/2024
-
MOL.TS.230.A:Somatic Mutation Testing-Solid TumorsEffective 07/01/2023 - 12/31/2023
-
MOL.TS.232.A: VeriStrat Testing for NSCLC TKI ResponseEffective 01/01/2024 - 01/11/2024
-
MOL.TS.232.A:VeriStrat Testing for NSCLC TKI ResponseEffective 07/01/2023 - 12/31/2023
-
MOL.TS.233.A: Von Hippel-Lindau Disease Genetic TestingEffective 01/01/2024 - 01/11/2024
-
MOL.TS.233.A:Von Hippel-Lindau Disease Genetic TestingEffective 07/01/2023 - 12/31/2023
-
MOL.TS.234.A: EndoPredict for Breast Cancer PrognosisEffective 01/01/2024 - 01/11/2024
-
MOL.TS.234.A:EndoPredict for Breast Cancer PrognosisEffective 07/01/2023 - 12/31/2023
-
MOL.TS.235.A: Exome SequencingEffective 01/01/2024 - 01/11/2024
-
MOL.TS.235.A:Exome SequencingEffective 07/01/2023 - 12/31/2023
-
MOL.TS.236.A: CxbladderEffective 01/01/2024 - 01/11/2024
-
MOL.TS.236.A:CxbladderEffective 07/01/2023 - 12/31/2023
-
MOL.TS.238.A: BRCA AnalysisEffective 01/01/2024 - 01/11/2024
-
MOL.TS.238.A:BRCA AnalysisEffective 07/01/2023 - 12/31/2023
-
MOL.TS.240.A: BCR-ABL Negative Myeloproliferative Neoplasm Genetic TestingEffective 01/01/2024 - 01/11/2024
-
MOL.TS.240.A:BCR-ABL Negative Myeloproliferative Neoplasm Genetic TestingEffective 07/01/2023 - 12/31/2023
-
MOL.TS.248.A: Breast Cancer Index for Breast Cancer PrognosisEffective 01/01/2024 - 01/11/2024
-
MOL.TS.248.A:Breast Cancer Index for Breast Cancer PrognosisEffective 07/01/2023 - 12/31/2023
-
MOL.TS.250.A: NETestEffective 01/01/2024 - 01/11/2024
-
MOL.TS.250.A:NETestEffective 07/01/2023 - 12/31/2023
-
MOL.TS.251.A: PALB2 Genetic Testing for Breast Cancer RiskEffective 01/01/2024 - 01/11/2024
-
MOL.TS.251.A:PALB2 Genetic Testing for Breast Cancer RiskEffective 07/01/2023 - 12/31/2023
-
MOL.TS.254.A: DecisionDX Uveal MelanomaEffective 01/01/2024 - 01/11/2024
-
MOL.TS.254.A:DecisionDx Uveal MelanomaEffective 07/01/2023 - 12/31/2023
-
MOL.TS.255.A: Oncotype DX Breast DCISEffective 01/01/2024 - 01/11/2024
-
MOL.TS.255.A:Oncotype DX Breast DCISEffective 07/01/2023 - 12/31/2023
-
MOL.TS.257.A: Epilepsy Genetic TestingEffective 01/01/2024 - 01/11/2024
-
MOL.TS.257.A:Epilepsy Genetic TestingEffective 07/01/2023 - 12/31/2023
-
MOL.TS.258.A: Maturity-Onset Diabetes of the Young (MODY) Genetic TestingEffective 01/01/2024 - 01/11/2024
-
MOL.TS.258.A:Maturity-Onset Diabetes of the Young Genetic TestingEffective 07/01/2023 - 12/31/2023
-
MOL.TS.259.A: ThyGeNEXT and ThyraMIR miRNA Gene Expression ClassifierEffective 01/01/2024 - 01/11/2024
-
MOL.TS.259.A:ThyGeNEXT and ThyraMIR miRNA Gene Expression ClassifierEffective 07/01/2023 - 12/31/2023
-
MOL.TS.260.A: OVA1Effective 01/01/2024 - 01/11/2024
-
MOL.TS.260.A:OVA1Effective 07/01/2023 - 12/31/2023
-
MOL.TS.261.A: Brugada Syndrome Genetic TestingEffective 01/01/2024 - 01/11/2024
-
MOL.TS.261.A:Brugada Syndrome Genetic TestingEffective 07/01/2023 - 12/31/2023
-
MOL.TS.264.A: SelectMDxEffective 01/01/2024 - 01/11/2024
-
MOL.TS.264.A:SelectMDxEffective 07/01/2023 - 12/31/2023
-
MOL.TS.266.A: Mitochondrial Disorders Genetic TestingEffective 01/01/2024 - 01/11/2024
-
MOL.TS.266.A:Mitochondrial Disorders Genetic TestingEffective 07/01/2023 - 12/31/2023
-
MOL.TS.267.A: Ehlers-Danlos Syndrome Genetic TestingEffective 01/01/2024 - 01/11/2024
-
MOL.TS.267.A:Ehlers-Danlos Syndrome Genetic TestingEffective 07/01/2023 - 12/31/2023
-
MOL.TS.268.A: Hereditary Connective Tissue Disorder Genetic TestingEffective 01/01/2024 - 01/11/2024
-
MOL.TS.268.A:Hereditary Connective Tissue Disorder TestingEffective 07/01/2023 - 12/31/2023
-
MOL.TS.269.A: Autism, Intellectual Disability, and Developmental Delay Genetic TestingEffective 01/01/2024 - 01/11/2024
-
MOL.TS.269.A:Autism, Intellectual Disability, and Developmental Delay Genetic TestingEffective 07/01/2023 - 12/31/2023
-
MOL.TS.270.A: ThyroseqEffective 01/01/2024 - 01/11/2024
-
MOL.TS.270.A:ThyroSeqEffective 07/01/2023 - 12/31/2023
-
MOL.TS.271.A: PancraGENEffective 01/01/2024 - 01/11/2024
-
MOL.TS.271.A:PancraGENEffective 07/01/2023 - 12/31/2023
-
MOL.TS.273.A: Nonsyndromic Hearing Loss and Deafness Genetic TestingEffective 01/01/2024 - 01/11/2024
-
MOL.TS.273.A:Nonsyndromic Hearing Loss and Deafness Genetic TestingEffective 07/01/2023 - 12/31/2023
-
MOL.TS.276.A: Polymerase Gamma (POLG) Related Disorders Genetic TestingEffective 01/01/2024 - 01/11/2024
-
MOL.TS.276.A:Polymerase Gamma (POLG) Related Disorders Genetic TestingEffective 07/01/2023 - 12/31/2023
-
MOL.TS.281.A: Arrhythmogenic Right Ventricular Cardiomyopathy Genetic TestingEffective 01/01/2024 - 01/11/2024
-
MOL.TS.281.A:Arrhythmogenic Right Ventricular Cardiomyopathy Genetic TestingEffective 07/01/2023 - 12/31/2023
-
MOL.TS.282.A: DermTech Pigmented Lesion AssayEffective 01/01/2024 - 01/11/2024
-
MOL.TS.282.A:DermTech Pigmented Lesion AssayEffective 07/01/2023 - 12/31/2023
-
MOL.TS.284.A: Dilated Cardiomyopathy Genetic TestingEffective 01/01/2024 - 01/11/2024
-
MOL.TS.284.A:Dilated Cardiomyopathy Genetic TestingEffective 07/01/2023 - 12/31/2023
-
MOL.TS.285.A: Multiple Endocrine Neoplasia Type 1 Genetic TestingEffective 01/01/2024 - 01/11/2024
-
MOL.TS.285.A:Multiple Endocrine Neoplasia Type 1 Genetic TestingEffective 07/01/2023 - 12/31/2023
-
MOL.TS.286.A: Multiple Endocrine Neoplasia Type 2 Genetic TestingEffective 01/01/2024 - 01/11/2024
-
MOL.TS.286.A:Multiple Endocrine Neoplasia Type 2 Genetic TestingEffective 07/01/2023 - 12/31/2023
-
MOL.TS.287.A:Hereditary Pancreatitis Genetic TestingEffective 07/01/2023 - 12/31/2023
-
MOL.TS.288.A: Limb-Girdle Muscular Dystrophy Genetic TestingEffective 01/01/2024 - 01/11/2024
-
MOL.TS.288.A:Limb-Girdle Muscular Dystrophy Genetic TestingEffective 07/01/2023 - 12/31/2023
-
MOL.TS.290.A: Facioscapulohumeral Muscular Dystrophy Genetic TestingEffective 01/01/2024 - 01/11/2024
-
MOL.TS.290.A:Facioscapulohumeral Muscular Dystrophy Genetic TestingEffective 07/01/2023 - 12/31/2023
-
MOL.TS.294.A: Decipher Prostate Cancer ClassifierEffective 01/01/2024 - 01/11/2024
-
MOL.TS.294.A:Decipher Prostate Cancer ClassifierEffective 07/01/2023 - 12/31/2023
-
MOL.TS.295.A: Genomic Prostate ScoreEffective 01/01/2024 - 01/11/2024
-
MOL.TS.295.A:Oncotype DX for Prostate CancerEffective 07/01/2023 - 12/31/2023
-
MOL.TS.297.A: ProlarisEffective 01/01/2024 - 01/11/2024
-
MOL.TS.297.A:ProlarisEffective 07/01/2023 - 12/31/2023
-
MOL.TS.301.A: Neurofibromatosis Type 1 Genetic TestingEffective 01/01/2024 - 01/11/2024
-
MOL.TS.301.A:Neurofibromatosis Type 1 Genetic TestingEffective 07/01/2023 - 12/31/2023
-
MOL.TS.302.A: Legius Syndrome Genetic TestingEffective 01/01/2024 - 01/11/2024
-
MOL.TS.302.A:Legius Syndrome Genetic TestingEffective 07/01/2023 - 12/31/2023
-
MOL.TS.306.A: Whole Genome SequencingEffective 01/01/2024 - 01/11/2024
-
MOL.TS.306.A:Whole Genome SequencingEffective 07/01/2023 - 12/31/2023
-
MOL.TS.307.A: AlloSure for Kidney Transplant RejectionEffective 01/01/2024 - 01/11/2024
-
MOL.TS.307.A:AlloSure for Kidney Transplant RejectionEffective 07/01/2023 - 12/31/2023
-
MOL.TS.308.A: Hemoglobinopathies Genetic TestingEffective 01/01/2024 - 01/11/2024
-
MOL.TS.308.A:Hemoglobinopathies Genetic TestingEffective 07/01/2023 - 12/31/2023
-
MOL.TS.309.A: Friedreich Ataxia Genetic TestingEffective 01/01/2024 - 01/11/2024
-
MOL.TS.309.A: Friedreich Ataxia Genetic TestingEffective 01/01/2024 - 01/11/2024
-
MOL.TS.309.A:Friedreich Ataxia Genetic TestingEffective 07/01/2023 - 12/31/2023
-
MOL.TS.310.A: Hereditary Ataxia Multigene Panel Genetic TestingEffective 01/01/2024 - 01/11/2024
-
MOL.TS.310.A:Hereditary Ataxia Multigene Panel Genetic TestingEffective 07/01/2023 - 12/31/2023
-
MOL.TS.311.A: Spinocerebellar Ataxia Genetic TestingEffective 01/01/2024 - 01/11/2024
-
MOL.TS.311.A:Spinocerebellar Ataxia Genetic TestingEffective 07/01/2023 - 12/31/2023
-
MOL.TS.312.A: Myotonic Dystrophy Type 1 Genetic TestingEffective 01/01/2024 - 01/11/2024
-
MOL.TS.312.A:Myotonic Dystrophy Type 1 Genetic TestingEffective 07/01/2023 - 12/31/2023
-
MOL.TS.313.A: Somatic Mutation Testing Hematological MalignanciesEffective 01/01/2024 - 01/11/2024
-
MOL.TS.313.A:Somatic Mutation Testing-Hematological MalignanciesEffective 07/01/2023 - 12/31/2023
-
MOL.TS.324.A: CHARGE Syndrome Genetic TestingEffective 01/01/2024 - 01/11/2024
-
MOL.TS.324.A:CHARGE Syndrome Genetic TestingEffective 07/01/2023 - 12/31/2023
-
MOL.TS.340.A: GeneSight Psychotropic TestEffective 01/01/2024 - 01/11/2024
-
MOL.TS.340.A:GeneSight Psychotropic TestEffective 07/01/2023 - 12/31/2023
-
MOL.TS.344.A: Chromosomal Microarray for Solid TumorsEffective 01/01/2024 - 01/11/2024
-
MOL.TS.344.A:Chromosomal Microarray for Solid TumorsEffective 07/01/2023 - 12/31/2023
-
MOL.TS.356.A: Microsatellite Instability and Immunohistochemistry Testing in CancerEffective 01/01/2024 - 01/11/2024
-
MOL.TS.356.A:Microsatellite Instability and Immunohistochemistry Testing in CancerEffective 07/01/2023 - 12/31/2023
-
MOL.TS.360.A: Inherited Bone Marrow Failure Syndrome (IBMFS) TestingEffective 01/01/2024 - 01/11/2024
-
MOL.TS.360.A:Inherited Bone Marrow Failure Syndrome (IBMFS) TestingEffective 07/01/2023 - 12/31/2023
-
MOL.TS.361.A: Human Platelet and Red Blood Cell Antigen GenotypingEffective 01/01/2024 - 01/11/2024
-
MOL.TS.361.A:Human Platelet and Red Blood Cell Antigen GenotypingEffective 07/01/2023 - 12/31/2023
-
MOL.TS.370.A: Inherited Thrombophilia Genetic TestingEffective 01/01/2024 - 01/11/2024
-
MOL.TS.370.A:Inherited Thrombophilia Genetic TestingEffective 07/01/2023 - 12/31/2023
-
MOL.TS.371.A: Noonan Spectrum Disorder Genetic TestingEffective 01/01/2024 - 01/11/2024
-
MOL.TS.371.A:Noonan Spectrum Disorder Genetic TestingEffective 07/01/2023 - 12/31/2023
-
MOL.TS.396.A: Multi-Cancer Early Detection ScreeningEffective 01/01/2024 - 01/11/2024
-
MOL.TS.396.A:Multi-Cancer Early Detection ScreeningEffective 07/01/2023 - 12/31/2023
-
MOL.TS.401.A: Liver Fibrosis Assessment BiomarkersEffective 01/01/2024 - 01/11/2024